MedTrace Logo

A Window of Opportunity Study of Black Raspberry for Patients With HNSCC

NCT06086925 · Status: WITHDRAWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL

Last updated 2025-07-11

No results posted yet for this study

Summary

The purpose of this phase 0 Window of Opportunity study is to have subjects with Head and Neck Squamous Cell Carcinoma (HNSCC) receive same dosage of Black Raspberry Extract between their cancer diagnosis and standard treatment (surgery). Tumor biopsies and research blood before and after the investigational treatment (Black Raspberry Extract lozenges) are collected for translational research. The investigational treatment is kept short to avoid delaying standard treatment.

Conditions

  • Squamous Cell Carcinoma of the Oral Cavity or Oropharynx

Interventions

DRUG

Black Raspberry

Each BRB contains 1 gram of black raspberry powder equal to roughly 6 black raspberries.

Sponsors & Collaborators

  • Mitchell Machtay

    lead OTHER

Principal Investigators

  • Mitchell Machtay, MD · Penn State Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-06-01
Primary Completion
2027-06-01
Completion
2027-12-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06086925 on ClinicalTrials.gov